SPOTLIGHT -
July 23rd 2025
Stay informed on PTSD treatment insights, including complex PTSD recognition, diagnostic nuances, and the link between migraines and trauma.
July 18th 2025
The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.
July 17th 2025
FDA reviewers raise concerns over Rexulti's efficacy for PTSD, highlighting discordant study results ahead of the advisory committee meeting.
July 16th 2025
The FDA advisory committee will review brexpiprazole for PTSD treatment, which could offer new hope after years without new options.
July 14th 2025
A psychiatrist reflects on the recent flooding tragedy in Texas.